The "Art" of Medicine and The "Smokescreen" of the Randomized Trial Off-Label Use of Vascular Devices

被引:5
|
作者
Ansel, Gary M. [1 ]
Jaff, Michael R. [2 ]
机构
[1] Univ Toledo, Sch Med, Ctr Crit Limb Care, Riverside Methodist Hosp, Columbus, OH 43214 USA
[2] Massachusetts Gen Hosp, Dept Med, Vasc Ctr, Div Cardiol Vasc Med, Boston, MA 02114 USA
关键词
peripheral vascular disease; stent; angioplasty; regulatory; off-label;
D O I
10.1002/ccd.21776
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Once a device is approved for sale in the United States by the Food and Drug Administration (FDA), it can legally be used by doctors to treat any condition a physician determines is medically appropriate. Based on postmarket published data and physician procedural experience, this may even become the standard of care when an alternative device either does not exist or is inferior in performance, even before FDA approval. This right of physicians to practice medicine without FDA approval is Federal law. The off-label use of medical devices for the treatment of peripheral vascular disease has recently become the latest target by groups with interests that have little to do with patient care. This interference has begun to negatively impact the latitude necessary for physicians to best treat their patients. (C) 2008 Wiley-Liss, Inc.
引用
收藏
页码:998 / 1002
页数:5
相关论文
共 50 条
  • [21] Off-label and unlicensed use of antidotes in paediatric patients
    Lifshitz, M
    Gavrilov, V
    Gorodischer, R
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 56 (11) : 839 - 841
  • [22] OFF-LABEL USE OF PSYCHOTROPIC MEDICATIONS: FOCUS ON ANTIDEPRESSANTS
    Marazziti, Donatella
    Golia, Francesca
    Carlini, Marina
    Botti, Francesco
    Dell'Osso, Liliana
    CLINICAL NEUROPSYCHIATRY, 2008, 5 (05): : 245 - 253
  • [23] Use of off-label drugs in neonatal intensive care
    Sucasas Alonso, Andrea
    Avila-Alvarez, Alejandro
    Combarro Eiriz, Marina
    Martinez Roca, Cristina
    Yanez Gomez, Pedro
    Codias Lopez, Alejandra
    Fernandez Trisac, Jose Luis
    Pertega Diaz, Sonia
    ANALES DE PEDIATRIA, 2019, 91 (04): : 237 - 243
  • [24] Off-label use of medicines in South Africa: a review
    Ngcobo, N. N.
    Mathibe, L. J.
    ORPHANET JOURNAL OF RARE DISEASES, 2024, 19 (01)
  • [25] Off-Label Use of Spesolimab in Dermatology: A Systematic Review
    Sood, Siddhartha
    Waked, Jihad
    Merchant, Nabil
    Abduelmula, Abrahim
    Mufti, Asfandyar
    Yeung, Jensen
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2025,
  • [26] Off-label use of ceftaroline fosamil: A systematic review
    Pani, Arianna
    Colombo, Fabrizio
    Agnelli, Francesca
    Frantellizzi, Viviana
    Baratta, Francesco
    Pastori, Daniele
    Scaglione, Francesco
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2019, 54 (05) : 562 - 571
  • [27] Off-Label Use of Tildrakizumab in Patients with Hidradenitis Suppurativa
    Maazi, Mahan
    Toy, Jeffrey
    Gui, Xi Yao
    Piguet, Vincent
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2024,
  • [28] The issue of whether studies involving off-label use of new devices need to be replaced by controlled studies
    Henkes, Hans
    NEURORADIOLOGY, 2010, 52 (11) : 1063 - 1064
  • [29] Patterns of Quetiapine Use in Psychiatric Inpatients: An Examination of Off-Label Use
    Philip, Noah S.
    Mello, Kerry
    Carpenter, Linda L.
    Tyrka, Audrey R.
    Price, Lawrence H.
    ANNALS OF CLINICAL PSYCHIATRY, 2008, 20 (01) : 15 - 20
  • [30] Classification and characteristics of on-label and off-label apixaban use in Denmark and Sweden
    Vinter, Nicklas
    Linder, Marie
    Andersen, Morten
    Pedersen, Alma B.
    Madsen, Morten
    Schachterle, Stephen E.
    Ataher, Quazi
    Mo, Jingping
    Johnsen, Soren Paaske
    Ehrenstein, Vera
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 (06) : 867 - 878